Top Markets
Coin of the day
Myriad Genetics, Inc. Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN
Classement en actions #16419
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company,... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Prix de l'action
$3.12
Dernière synchronisation: 2026-09-01
Capitalisation boursière
$294.21M
Changement (1 jour)
-3.26%
Changement (1 an)
-54.86%
Pays
US
Échange Myriad Genetics, Inc. (MYGN)

Catégorie

Nombre d'actions en circulation pour Myriad Genetics, Inc. (MYGN)
Nombre d'actions en circulation au September 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Myriad Genetics, Inc., le nombre actuel d'actions en circulation est de 0. À la fin de September 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Myriad Genetics, Inc. (MYGN) de 2026 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
Pas assez de données pour les dates fournies.
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
371.00M -
US
705.30M -
US
- -
CN
143.28M -
US
80.10M -
US